|1.||Rosano, Giuseppe M C: 13 articles (01/2016 - 11/2003)|
|2.||Fragasso, Gabriele: 13 articles (01/2016 - 02/2002)|
|3.||Margonato, Alberto: 11 articles (07/2014 - 02/2002)|
|4.||Vitale, Cristiana: 11 articles (09/2013 - 11/2003)|
|5.||Volterrani, Maurizio: 8 articles (09/2013 - 10/2004)|
|6.||Fini, Massimo: 8 articles (04/2011 - 11/2003)|
|7.||Marazzi, Giuseppe: 6 articles (03/2013 - 02/2005)|
|8.||Belardinelli, Romualdo: 6 articles (03/2013 - 03/2004)|
|9.||Calori, Giliola: 6 articles (03/2013 - 02/2002)|
|10.||Marzilli, Mario: 6 articles (01/2011 - 01/2003)|
|1.||Myocardial Ischemia (Ischemic Heart Diseases)
09/30/2013 - "Trimetazidine (TMZ) is a metabolic agent of proven efficacy in improving myocardial ischemia and angina. "
02/01/2005 - "To assess whether the metabolic anti-ischemic agent, trimetazidine, is effective in controlling episodes of myocardial ischemia during sexual activity in patients who have CAD and use long-term nitrate therapy, we studied 38 men (57 +/- 6 years of age) who had proved CAD. "
03/01/2004 - "Adjunctive therapy with metabolic agents, such as trimetazidine, to standard care of elderly patients with ischemic heart disease may be particularly useful in the treatment of angina. "
01/01/2011 - "It is necessary to emphasize that analysis of results of the PRIMA study has revealed similar efficacy of trimetazidine MR in men and women what allows to recommend this metabolic myocardial cytoprotector to patients with ischemic heart disease irrespective of gender."
01/01/2003 - "[Clinical efficacy of myocardial cytoprotector trimetazidine in peri- and postmenopausal women with ischemic heart disease]."
07/01/2005 - "Heart function was significantly improved by trimetazidine after ischemia, but only in hypertrophied hearts, with function improving to values in untreated control hearts. "
12/01/2003 - "The major objective of this study was to investigate the cardio-protective effects of trimetazidine in prolonged global ischemia subjected Langendorff perfused rat hearts. "
07/01/2007 - "In nondiabetic patients with stable angina, combined treatment with hemodynamic agents and trimetazidine is well-tolerated and effective in controlling ischemia. "
01/01/2007 - "Supplementation of standard anti-ischemic therapy with cytoprotective preparation trimetazidine MB (Preductal MB) revealed greater efficacy of treatment manifesting not only by decrease of functional class in observed patients but also by increase of volume of performed physical load, decrease of episodes of ischemia during 24 hours (according to Holter monitoring data), as well as decrease of mean duration of ischemia (painful and painless). "
06/01/2003 - "To investigate the protective effects of trimetazidine on rabbit myocardium in ischemia and reperfusion. "
05/01/2001 - "In summary, clinical data indicate that trimetazidine is a safe, effective treatment for the symptoms of stable angina pectoris when used either as a monotherapy or an adjunctive therapy. "
07/01/1999 - "Trimetazidine is an effective and well tolerated anti-ischaemic agent which, in addition to providing symptom relief and functional improvement in patients with angina pectoris, has a cytoprotective action during ischaemia. "
12/20/2014 - "The efficacy of trimetazidine on stable angina pectoris: a meta-analysis of randomized clinical trials."
01/01/2002 - "To study efficacy of trimetazidine including action on quality of life in patients over 65 years of age with stable angina pectoris. "
12/20/2014 - "This meta-analysis confirms the efficacy of trimetazidine in the treatment of stable angina pectoris, in comparison with conventional antianginal agents, regardless of treatment duration."
08/01/2009 - "Adding trimetazidine to optimal medical therapy in patients with heart failure of ischemic origin may improve heart rate variability in association with improved left ventricular ejection fraction."
01/01/2014 - "Is treatment with trimetazidine beneficial in patients with chronic heart failure?"
07/01/2009 - "Improved left and right ventricular functions with trimetazidine in patients with heart failure: a tissue Doppler study."
08/01/2009 - "Chronic administration of trimetazidine in addition to the conventional therapy has been shown to improve functional class and left ventricular functions of heart failure patients. "
02/01/2009 - "Trimetazidine, a metabolic modulator, has been reported to improve cardiac function in heart failure (HF) patients. "
08/24/1995 - "It is concluded that pretreatment with trimetazidine in the blood-perfused rabbit heart is effective in reducing myocardial infarct size."
05/01/1993 - "It is concluded that pretreatment with trimetazidine in the blood perfused rabbit heart is effective in reducing myocardial infarct size."
04/01/2009 - "Physical QOL, evaluated by a MacNew Quality of Life After Myocardial Infarction questionnaire (MacNewQLMI), improved in patients randomized to trimetazidine but not in those allocated to placebo (32%+/-5% vs. -1%+/-3%, P<0.01). "
01/01/2008 - "The purpose of the study was to assess efficiency of the use of trimetazidine (Preductal MR) in therapy of acute myocardial infarction (MI) on the grounds of examination of oxidative potential of erythrocytes and blood serum, antioxidative enzyme activity. "
08/01/2007 - "[Clinical study of trimetazidine for myocardial protection in acute myocardial infarction]."
|10.||Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)
|2.||Induced Heart Arrest (Cardioplegia)
|3.||Drug Therapy (Chemotherapy)
|4.||Coronary Artery Bypass (Coronary Artery Bypass Surgery)
|5.||Angioplasty (Angioplasty, Transluminal)